Takeda Pharmaceutical Co Ltd
4502: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥5,982.00 | Jdmkz | Ldgskkgx |
Takeda’s Q3 Earnings in Line, Enjoying Strong Foreign Exchange Tailwinds; Shares Fairly Valued
Narrow-moat Takeda’s third-quarter fiscal result was in line with our expectations after adjusting for currency tailwinds due to a depreciating Japanese yen. Revenue was JPY 1,096.6 billion, which is 21.7% year-on-year growth, but only 2.6% growth after adjusting for currency. Core operating profit was JPY 330 billion, representing 30% core operating profit margin.